搜索
ss
ss
新闻动态
News Center
Location:
Homepage
/
/
/
/
Biotheus Announces the Completion of the Third Round of Financing

Biotheus Announces the Completion of the Third Round of Financing

  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-29
  • Views:0

(Summary description)Recently, Biotheus announced the successful completion of a third round of financing. This round of financing is jointly funded by leading investor New Alliance Capital, new investors HANNE Capital, etc., and original investors Highlight Capital, Shiyu Capital and HuaJin Capital.

Since its establishment in 2018, Biotheus has constructed a product portfolio of over 10 monoclonal antibody and biospecific antibody categoryⅠinnovative biological drugs, covering treatment fields of tumors and metabolic diseases. The first bispecific antibody new drug (PM8001) has been approved and is under phase I clinical research. PM8001 is based on single domain antibody with small molecular weight and good stability, it targets two tumor related targets including PD-L1 at the same time, so as to improve the anti-tumor activity and curative effect. It is expected to provide brand new clinical solutions for cancer patients after market launched in the future. According to the product chain development plan, 5 innovative drugs are expected to enter clinical research phase by the end of 2021. At the same time, in the process of product chain development, Biotheus will also actively seek strategic cooperation in many aspects to quickly advance the process of new drug development.

"Over the past two years, with the support of investors and local governments and the joint efforts of the team, Biotheus has made smooth progress in product development, improvement of R&D facilities and team construction, and successfully completed all set goals." Mr. Liu Xiaolin, President of Biotheus, said, "I'm glad that the achievements and development potential of the company have been recognized by new investors such as New Alliance Capital. We have completed three rounds of financing. This is the largest one, and all the funds obtained will be used to support the development of new drugs and enterprise operation of the company."

Mr. Wu Zonghe, partner of New Alliance Capital indicated: "Just two years after its establishment, Biotheus has emerged in the domestic biomedical industry and developed very rapidly. We recognize Biotheus’ corporate philosophy and future development plan, and hope that our participation can help Biotheus quickly promote the development progress of innovative drug product portfolio, strive for the early launching of new drugs and benefit the majority of patients."

Ms. Jiang Yanye, spokesman of Highlight Capital stated: "Since the start of Biotheus, we have been paying attention to the company and supporting the development of it. We are very happy and gratified to see the achievements made by Biotheus in the past two years. In the future, we will continue to spare no effort to provide support and help and grow together with Biotheus."

About Biotheus

Biotheus was incorporated in 2018 and has carried on its start-up vision “to inspire each other and create effective drugs for humankind”, as well as focused on malignant tumors and metabolic diseases while dedicating to the R&D and industrialization of the national category I innovative biological drugs, prioritizing the R&D of a new generation dual targeting antibody drug. Since the establishment of Biotheus, three rounds of financing have been completed. Meanwhile, it entered into a cooperation agreement with Zhuhai Gaoxin District Government and received several supporting measures from the Gaoxin District Government as a result, while being recognized as Zhuhai Unicorn Enterprise (potential enterprise).

About New Alliance Capital








Founded in 2008, New Alliance Capital is a fund management company focusing on private equity and venture capital. It manages a number of funds with total assets of more than 10 billion RMB. Its main investors include well-known state-owned enterprise groups, professional master funds, government guidance funds and listed companies. The main investment directions of New Alliance Capital include science and technology / media, medical and health fields, covering early phase, growth phase, mature phase and other phases. So far, more than 70 investments have been completed, including more than 20 IPO / listing enterprises at home and abroad, and a number of industry leaders have been cultivated.







Biotheus Announces the Completion of the Third Round of Financing

(Summary description)Recently, Biotheus announced the successful completion of a third round of financing. This round of financing is jointly funded by leading investor New Alliance Capital, new investors HANNE Capital, etc., and original investors Highlight Capital, Shiyu Capital and HuaJin Capital.

Since its establishment in 2018, Biotheus has constructed a product portfolio of over 10 monoclonal antibody and biospecific antibody categoryⅠinnovative biological drugs, covering treatment fields of tumors and metabolic diseases. The first bispecific antibody new drug (PM8001) has been approved and is under phase I clinical research. PM8001 is based on single domain antibody with small molecular weight and good stability, it targets two tumor related targets including PD-L1 at the same time, so as to improve the anti-tumor activity and curative effect. It is expected to provide brand new clinical solutions for cancer patients after market launched in the future. According to the product chain development plan, 5 innovative drugs are expected to enter clinical research phase by the end of 2021. At the same time, in the process of product chain development, Biotheus will also actively seek strategic cooperation in many aspects to quickly advance the process of new drug development.

"Over the past two years, with the support of investors and local governments and the joint efforts of the team, Biotheus has made smooth progress in product development, improvement of R&D facilities and team construction, and successfully completed all set goals." Mr. Liu Xiaolin, President of Biotheus, said, "I'm glad that the achievements and development potential of the company have been recognized by new investors such as New Alliance Capital. We have completed three rounds of financing. This is the largest one, and all the funds obtained will be used to support the development of new drugs and enterprise operation of the company."

Mr. Wu Zonghe, partner of New Alliance Capital indicated: "Just two years after its establishment, Biotheus has emerged in the domestic biomedical industry and developed very rapidly. We recognize Biotheus’ corporate philosophy and future development plan, and hope that our participation can help Biotheus quickly promote the development progress of innovative drug product portfolio, strive for the early launching of new drugs and benefit the majority of patients."

Ms. Jiang Yanye, spokesman of Highlight Capital stated: "Since the start of Biotheus, we have been paying attention to the company and supporting the development of it. We are very happy and gratified to see the achievements made by Biotheus in the past two years. In the future, we will continue to spare no effort to provide support and help and grow together with Biotheus."

About Biotheus

Biotheus was incorporated in 2018 and has carried on its start-up vision “to inspire each other and create effective drugs for humankind”, as well as focused on malignant tumors and metabolic diseases while dedicating to the R&D and industrialization of the national category I innovative biological drugs, prioritizing the R&D of a new generation dual targeting antibody drug. Since the establishment of Biotheus, three rounds of financing have been completed. Meanwhile, it entered into a cooperation agreement with Zhuhai Gaoxin District Government and received several supporting measures from the Gaoxin District Government as a result, while being recognized as Zhuhai Unicorn Enterprise (potential enterprise).

About New Alliance Capital








Founded in 2008, New Alliance Capital is a fund management company focusing on private equity and venture capital. It manages a number of funds with total assets of more than 10 billion RMB. Its main investors include well-known state-owned enterprise groups, professional master funds, government guidance funds and listed companies. The main investment directions of New Alliance Capital include science and technology / media, medical and health fields, covering early phase, growth phase, mature phase and other phases. So far, more than 70 investments have been completed, including more than 20 IPO / listing enterprises at home and abroad, and a number of industry leaders have been cultivated.







  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-29
  • Views:0
Information

Recently, Biotheus announced the successful completion of a third round of financing. This round of financing is jointly funded by leading investor New Alliance Capital, new investors HANNE Capital, etc., and original investors Highlight Capital, Shiyu Capital and HuaJin Capital.

Since its establishment in 2018, Biotheus has constructed a product portfolio of over 10 monoclonal antibody and biospecific antibody categoryinnovative biological drugs, covering treatment fields of tumors and metabolic diseases. The first bispecific antibody new drug (PM8001) has been approved and is under phase I clinical research. PM8001 is based on single domain antibody with small molecular weight and good stability, it targets two tumor related targets including PD-L1 at the same time, so as to improve the anti-tumor activity and curative effect. It is expected to provide brand new clinical solutions for cancer patients after market launched in the future. According to the product chain development plan, 5 innovative drugs are expected to enter clinical research phase by the end of 2021. At the same time, in the process of product chain development, Biotheus will also actively seek strategic cooperation in many aspects to quickly advance the process of new drug development.

"Over the past two years, with the support of investors and local governments and the joint efforts of the team, Biotheus has made smooth progress in product development, improvement of R&D facilities and team construction, and successfully completed all set goals." Mr. Liu Xiaolin, President of Biotheus, said, "I'm glad that the achievements and development potential of the company have been recognized by new investors such as New Alliance Capital. We have completed three rounds of financing. This is the largest one, and all the funds obtained will be used to support the development of new drugs and enterprise operation of the company."

Mr. Wu Zonghe, partner of New Alliance Capital indicated: "Just two years after its establishment, Biotheus has emerged in the domestic biomedical industry and developed very rapidly. We recognize Biotheus’ corporate philosophy and future development plan, and hope that our participation can help Biotheus quickly promote the development progress of innovative drug product portfolio, strive for the early launching of new drugs and benefit the majority of patients."

Ms. Jiang Yanye, spokesman of Highlight Capital stated: "Since the start of Biotheus, we have been paying attention to the company and supporting the development of it. We are very happy and gratified to see the achievements made by Biotheus in the past two years. In the future, we will continue to spare no effort to provide support and help and grow together with Biotheus."

About Biotheus

Biotheus was incorporated in 2018 and has carried on its start-up vision “to inspire each other and create effective drugs for humankind”, as well as focused on malignant tumors and metabolic diseases while dedicating to the R&D and industrialization of the national category I innovative biological drugs, prioritizing the R&D of a new generation dual targeting antibody drug. Since the establishment of Biotheus, three rounds of financing have been completed. Meanwhile, it entered into a cooperation agreement with Zhuhai Gaoxin District Government and received several supporting measures from the Gaoxin District Government as a result, while being recognized as Zhuhai Unicorn Enterprise (potential enterprise).

About New Alliance Capital

Founded in 2008, New Alliance Capital is a fund management company focusing on private equity and venture capital. It manages a number of funds with total assets of more than 10 billion RMB. Its main investors include well-known state-owned enterprise groups, professional master funds, government guidance funds and listed companies. The main investment directions of New Alliance Capital include science and technology / media, medical and health fields, covering early phase, growth phase, mature phase and other phases. So far, more than 70 investments have been completed, including more than 20 IPO / listing enterprises at home and abroad, and a number of industry leaders have been cultivated.

Keyword:

Scan the QR code to read on your phone

Back to list

Recommend

Copyright: © 2021 Biotheus, Inc.     粤ICP备2021122492号      Powered by www.300.cn